精品伊人久久大香线蕉,开心久久婷婷综合中文字幕,杏田冲梨,人妻无码aⅴ不卡中文字幕

打開APP
userphoto
未登錄

開通VIP,暢享免費電子書等14項超值服

開通VIP
Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insig

Abstract

Background—Intensive risk factor modification significantly improves outcomes for patients with diabetes and cardiovascular disease (CVD). However, the degree to which secondary prevention treatment goals are achieved in international clinical practice is unknown.

Methods—Attainment of 5 secondary prevention parameters—aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin therapy), blood pressure control (<140 mmHg systolic, <90 mmHg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and non-smoking status—was evaluated among 13,616 patients from 38 countries with diabetes and known CVD at entry into TECOS. Logistic regression was used to evaluate the association between individual and regional factors and secondary prevention achievement at baseline. Cox proportional hazards regression analysis was used to determine the association between baseline secondary prevention achievement and cardiovascular death, myocardial infarction, or stroke.

Results—Overall, 29.9% of patients with diabetes and CVD achieved all 5 secondary prevention parameters at baseline, although 71.8% achieved at least 4 parameters. North America had the highest proportion (41.2%), whereas Western Europe, Eastern Europe, and Latin America had proportions of approximately 25%. Individually, blood pressure control (57.9%) had the lowest overall attainment while non-smoking status had the highest (89%). Over a median 3.0 years of follow-up, a higher baseline secondary prevention score was associated with improved outcomes in a step-wise graded relationship (adjusted HR 0.60 [95% CI 0.47-0.77] for those patients achieving all 5 measures versus those achieving ≤2).

Conclusions—In an international trial population, significant opportunities exist to improve the quality of cardiovascular secondary prevention care among patients with diabetes and CVD, which in turn could lead to reduced risk of downstream cardiovascular events.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00790205

本站僅提供存儲服務,所有內容均由用戶發布,如發現有害或侵權內容,請點擊舉報
打開APP,閱讀全文并永久保存 查看更多類似文章
猜你喜歡
類似文章
Prevention of diabetes-induced cardiovascular complications upon- by Yan Jun Xu et al
阿司匹林走下神壇了嗎?
2022+APSC臨床實踐聲明:體育活動,心肺適應能力和心血管健康—第Ⅱ部分英文版
美國預防服務工作組推薦意見聲明
柳葉刀、NEJM:神藥折戟!兩項大規模臨床試驗證實,阿司匹林對糖尿病患者和心血管病中低危人群的心血管...
老年人心臟病發作后補充ω
更多類似文章 >>
生活服務
分享 收藏 導長圖 關注 下載文章
綁定賬號成功
后續可登錄賬號暢享VIP特權!
如果VIP功能使用有故障,
可點擊這里聯系客服!

聯系客服

主站蜘蛛池模板: 新巴尔虎右旗| 开原市| 桑植县| 新竹市| 逊克县| 申扎县| 芦山县| 福鼎市| 桃源县| 名山县| 兴安盟| 吉首市| 桃源县| 梅河口市| 海宁市| 禹州市| 曲靖市| 淅川县| 梁平县| 白山市| 赤水市| 清河县| 务川| 青岛市| 堆龙德庆县| 射洪县| 玉门市| 沙坪坝区| 泰来县| 大洼县| 石首市| 罗甸县| 翁源县| 滨海县| 宾川县| 崇阳县| 崇信县| 平利县| 伊吾县| 周至县| 名山县|